SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September
2005
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrants name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrants security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If Yes is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
|
210, 1167 Kensington Crescent NW
Calgary, Alberta
Canada T2N 1X7 |
For Immediate Release
Oncolytics Biotech Inc. Announces Appointment of Chief Medical Officer
CALGARY, AB, September 27, 2005 - Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY)
announced today the appointment of Karl Mettinger, MD, PhD, as Chief Medical Officer.
Dr. Mettinger has been involved with the clinical and regulatory approval of oncology,
cardiovascular, and other products in the pharmaceutical industry for twenty years, said Dr. Brad
Thompson, President and CEO of Oncolytics. His record includes the implementation of clinical
studies for more than 25,000 patients worldwide. As part of our senior medical and scientific
management group which includes Dr. Gill and Dr. Coffey, Dr. Mettinger is expected to develop the
clinical trial program which best supports a registration path for REOLYSIN®.
Dr. Mettinger has been involved in clinical and regulatory affairs with various pharmaceutical
companies since 1985. Prior to joining Oncolytics, he was Senior Vice President and Chief Medical
Officer with SuperGen Inc. Prior to that, he was Executive Director, Clinical Research at
IVAX/Baker Norton, which is the new drug subsidiary of IVAX Corporation. He began his career in
the industry with KABI in Sweden. Dr. Mettinger holds an MD from the University of Lund in Sweden
and a PhD (hematology/stroke) from the Karolinska Institute in Stockholm, Sweden. He is a member
of numerous medical and scientific associations including the American Association of Clinical
Oncology, the American Society of Hematology and the American Association of Cancer Research.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its
proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics
researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in
vitro, kill human cancer cells that are derived from many types of cancer including breast,
bladder, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer
treatment results in a number of animal models. Phase I clinical trial results have indicated that
REOLYSIN® was well tolerated and that the reovirus demonstrated activity
in tumours injected with REOLYSIN®.
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the impact
Dr. Mettinger will have on the development towards a registration path, the Companys expectations
related to the advancement of REOLYSIN through the clinical and regulatory process, and the
Companys belief as to the potential of REOLYSIN® as a cancer therapeutic, alone, or in combination
with other therapies, involve known and unknown risks and uncertainties, which could cause the
Companys actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical
studies and trials, the Companys ability to successfully commercialize REOLYSIN®, uncertainties
related to the research and development of pharmaceuticals, uncertainties related to the regulatory
process and general changes to the economic environment. Investors should consult the Companys
quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group |
Dr. Brad Thompson
|
|
Joanna Longo |
210, 1167 Kensington Cr NW
|
|
20 Toronto Street |
Calgary, Alberta T2N 1X7
|
|
Toronto, Ontario M5C 2B8 |
Tel: 403.670.7377
|
|
Tel: 416.815.0700 ext. 233 |
Fax: 403.283.0858
|
|
Fax: 416.815.0080 |
www.oncolyticsbiotech.com
|
|
jlongo@equicomgroup.com |
|
|
|
The Investor Relations Group
|
|
RenMark Financial Communications |
Janet Vasquez
|
|
John Boidman |
11 Stone St, 3rd Floor
|
|
2080 Rene Levesque Blvd. W. |
New York, NY 10004
|
|
Montreal, PQ H3H 1R6 |
Tel: 212.825.3210
|
|
Tel: 514.939.3989 |
Fax: 212.825.3229
|
|
Fax: 514.939.3717 |
jvasquez@investorrelationsgroup.com
|
|
jboidman@renmarkfinancial.com |
-30-